Qualcomm vs Arm: Jury to Resume Deliberations in High-Stakes Chip Licensing Dispute
The legal battle between Qualcomm and Arm Holdings has reached another critical stage, with a US jury set to resume deliberations next week after failing to reach a verdict on October 9, 2026. The dispute centres on allegations that Arm breached licensing agreements and deliberately interfered with Qualcomm's business dealings with Meta Platforms. Arm denies that Qualcomm suffered the harm alleged in the lawsuit.
The case goes beyond a disagreement between two technology companies. Qualcomm develops processors used in smartphones, personal computers and other connected devices, while Arm supplies the underlying processor architecture used by many chipmakers. Their commercial relationship therefore touches a broad section of the global semiconductor industry.
The outcome could influence how the companies negotiate licensing terms, how Qualcomm manages its dependence on Arm technology and how future disputes over chip intellectual property are resolved.
For investors following Qualcomm stock (NASDAQ: QCOM) and Arm stock (NASDAQ: ARM), the immediate focus is the jury's decision. However, the longer-term significance lies in the economics of semiconductor licensing and the balance of power between technology developers and chip manufacturers.
What Is the Qualcomm–Arm Dispute About?
The latest trial, held in federal court in Wilmington, Delaware, ran for five days and is the second major courtroom confrontation between the companies in two years.
Qualcomm alleges that Arm failed to meet contractual obligations by withholding software patches and chip-design tools. It also claims Arm breached a pricing agreement intended to ensure Qualcomm did not pay more than 10% above the lowest price charged for comparable Arm processor designs.
A further allegation concerns Qualcomm's negotiations with Meta. Qualcomm argues that Arm disclosed a 2024 letter to Bloomberg in which it threatened to terminate a key licensing agreement, potentially damaging negotiations over a chip deal valued at approximately $170 million.
Arm disputes Qualcomm's claims and argues that the company did not suffer the alleged harm. It has characterised the litigation as an attempt by Qualcomm to gain leverage in disagreements over licensing terms. These remain competing positions, not established findings of wrongdoing.
The jury deliberated for approximately four hours on Friday without reaching a verdict. It is scheduled to return on Tuesday, October 13, according to Reuters' reporting.
A related trial without a jury is also examining whether Arm negotiated in good faith over licensing terms. The judge's decision in that proceeding may come separately from the jury's verdict.
Why the Royalty Dispute Could Have Major Financial Consequences
One of the most consequential elements of the case is Qualcomm's request for permission to stop paying royalties to Arm for up to five years if a contractual breach is established.
Royalties are payments made for the right to use intellectual property. In the semiconductor industry, chipmakers often pay licensing fees and royalties to use processor designs, instruction sets and other technologies developed by specialist firms.
Arm's business model has historically relied heavily on licensing its architecture and collecting royalties when customers use that technology in chips. Qualcomm, meanwhile, uses Arm's architecture as the foundation for its own processor designs, including Snapdragon products.
If Qualcomm were allowed to suspend royalty payments for five years, the financial consequences for Arm could be substantial. Reuters has reported that the potential exposure could run into billions of dollars, although the actual amount would depend on the court's findings and the relevant contractual provisions.
The judge has not yet ruled on whether the requested five-year royalty suspension is enforceable. Arm has challenged that provision. Qualcomm's request should therefore not be mistaken for a confirmed entitlement to stop paying.
The court's decisions on contractual liability, damages and the separate good-faith question will determine the practical consequences.
Why Arm's Licensing Model Is Under Pressure
The disagreement reflects a broader tension in the semiconductor industry.
Arm develops processor architecture and licenses it to companies that build their own chips. Its technology is used across smartphones, computers, servers and other electronic devices. This model allows Arm to earn revenue from a wide ecosystem without manufacturing every chip itself.
Qualcomm takes a different approach. It designs and sells processors, modems and related technologies to device manufacturers. It also operates a patent-licensing business.
The relationship can be commercially beneficial: Arm supplies foundational technology, while Qualcomm develops differentiated products for specific markets.
But the relationship becomes more complicated when the technology supplier changes its commercial ambitions.
Since SoftBank took control of Arm in 2016, Arm has increasingly pursued opportunities beyond its traditional licensing business, including developing and selling its own chips. That shift has heightened tensions over licensing terms, pricing and the relationship between Arm's architecture business and its own product ambitions.
For customers such as Qualcomm, the central concern is whether access to essential technology remains predictable and commercially sustainable.
For Arm, the challenge is to protect the value of its intellectual property while maintaining relationships with companies that depend on its designs.
What the Case Means for Qualcomm Stock
For investors tracking Qualcomm, the dispute carries both financial and strategic implications.
Potential royalty savings: If Qualcomm successfully establishes a contractual breach and secures the requested remedy, it could potentially avoid significant royalty payments. But the size and availability of any benefit remain uncertain.
Business continuity: Qualcomm's processor business depends on continued access to Arm's architecture. Its existing licence runs through 2033, according to Reuters. The litigation makes the terms governing future technology access particularly important.
Legal and operational risk: Even if Qualcomm wins key arguments, the company may still face prolonged negotiations, further litigation or uncertainty over future licensing arrangements.
The case is not simply about whether Qualcomm receives compensation. It also concerns the commercial terms under which the company can continue developing processors for future devices.
Qualcomm has been expanding beyond its traditional smartphone-chip business into personal computers and other markets. Predictable access to processor architecture is therefore relevant to its longer-term product strategy.
What the Case Means for Arm Stock
Arm Holdings faces a different set of risks.
Its licensing and royalty model depends on customers continuing to use its architecture and paying under agreed terms. A ruling that weakens Arm's contractual position could affect its negotiations with Qualcomm and potentially influence how other customers approach future agreements.
The potential financial consequences should not be overstated before the court rules. Qualcomm's request to stop royalty payments is contested, and the jury must first consider the allegations presented to it.
Investors should also distinguish between the current contractual dispute and Arm's broader growth opportunities. Demand for semiconductor technology in artificial intelligence, data centres, smartphones and personal computers can influence Arm's prospects independently of this case.
The legal outcome may affect perceptions of licensing risk, but it will not by itself determine the company's entire future revenue trajectory.
Could the Verdict Affect the Wider Semiconductor Industry?
The dispute could have implications beyond the two companies because Arm's architecture is embedded in a large ecosystem of chip designers and device manufacturers.
If the litigation establishes clearer limits on how licensing agreements can be enforced, it could influence future negotiations across the industry. Conversely, a prolonged dispute could increase uncertainty for companies planning products around licensed processor technology.
The case also highlights a key issue for chipmakers: intellectual property is not merely a legal asset but a critical production input. Uncertainty over access, pricing or contractual obligations can affect product development and long-term planning.
However, it would be premature to conclude that the verdict will immediately change licensing agreements across the semiconductor industry. Any broader effect will depend on the court's reasoning, the contractual language involved and how other companies respond.
What Investors Should Watch Next
The immediate catalyst is the jury's return to deliberations on October 13. Investors should watch for several developments:
The jury's verdict: Whether it finds that Arm breached the relevant agreements or interfered with Qualcomm's dealings.
The judge's ruling: Whether the requested five-year royalty suspension is enforceable.
The separate bench trial: Whether the court finds that Arm negotiated in good faith over licensing terms.
Future negotiations: Whether the legal outcome changes the companies' approach to licensing and architecture access.
Company disclosures: Any subsequent updates about financial exposure, royalty obligations or business strategy.
A verdict against either party would not necessarily settle every issue. Contractual remedies, the separate court proceeding and potential further legal steps could continue to shape the dispute.
Conclusion
Qualcomm and Arm's latest courtroom battle puts the economics of semiconductor licensing under the spotlight. Qualcomm is seeking remedies over alleged contractual breaches and interference with a potential Meta deal, while Arm disputes the claims and argues that Qualcomm has not suffered the alleged harm.
For investors, the verdict could influence the companies' future royalty arrangements, legal exposure and negotiating positions. The most important next step is the jury's decision, followed by the judge's ruling on the requested remedies and the separate question of good-faith negotiations.
Follow our blog for more updates on semiconductor companies, technology stocks, business developments and global markets.
Disclaimer: This article is for informational and educational purposes only and should not be considered investment advice